First In Human Study of CX-2051 in Advanced Solid Tumors
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Metastatic or locally advanced unresectable solid tumor that has progressed afte... [+4]
Recent history (within last 2 years) of localized cancers that are not related t... [+8]